Genome & Co. · KRX:314130
Genome & — Investor Presentation (June 2025)
35 slides from Genome &'s investor presentation, June 2025
Slide 1: Corporate Presentation – Investor Relations 2025
Corporate Presentation Investor Relations 2025 June, 2025 Genome & Company
Slide 2: Disclaimer
Disclaimer o This document has been orepared by Genome & Compan contained in this document have not been subjected to individual verificatior V s document lays aut the Company's anticipated business and financial performance and includes expressions such as “anticipation”, “forecast” “pla environmen
Slide 3: Table of Contents
Table of Contents INVESTOR RELATIONS 2025 I. Company Overview II. GENA-104 (EP0089) Out-Licensing III. Microbiome Commercialization (UIQ Cosmetics) IV.Strategy (Vision) The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is
Slide 4: Company Overview
Company Overview INVESTOR RELATIONS 2025 Company Overview Business Areas Company Genome & Company, Inc Name Hong Yooseok CEOs Pae Jisoo Park Hansoo R&D Business Date of 2015.09.24 Incorporation Medical Paid-in ADC grade ₩16.4 Billion (As of Mar. 2025) probiotics Capital Total 100 employees (As of Ma
Slide 5: Leadership
Leadership INVESTOR RELATIONS 2025 Hong Yooseok Park Hansoo Pae Jisoo CEO CTO CEO Hankuk University of Foreign Studies, B.A. Seoul National University, MD Seoul National University, MD Wharton School, University of Pennsylvania, Seoul National University, Ph.D. in Medicine Duke University, MBA MBA 2
Slide 6: Genome & Company Organization Hierarchy
Genome & Company Organization Hierarchy INVESTOR RELATIONS 2025 Yooseok Hong, CEO Jisoo Pae, CEO Hansoo Park, CTO Business Management Research& Development HR & Finances Microbiome Research New Drug Research Development Consumer Business Group Health care BusinessDept. Group Group Communication Grou
Slide 7: Table of Contents
Table of Contents INVESTOR RELATIONS 2025 I. Company Overview II. GENA-104 (EP0089) Out-Licensing III. Microbiome Commercialization (UIQ Cosmetics) IV.Strategy (Vision) The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is
Slide 8: May 2024 Debiopharm Out-Licensing (Debio0633): Process & Significance
May 2024 Debiopharm Out-Licensing(Debio0633) : Process & Significance INVESTOR RELATIONS 2025 Early Preclinical Development Target Discovery Antibody Linker & Payload Clinical Development & Development & Stages & Validation Discovery Discovery Commercialization CMC Roles Joint Research Initiated Out
Slide 9: Debiopharm
Debiopharm INVESTOR RELATIONS 2025 Drug Development in Oxaliplatin Oncology & Bacterial Infections Colorectal, Pancreatic & Gastric Cancers Total sales • Sanofi (Eloxatin® , >25years) $ 22 bil 2 Registered compounds • Dr. Reddy’s Laboratories (Dacotin® , > 20years) Oxaliplatin • Yakult (Elplat® , >1
Slide 10: GENA-104(EP0089) Out-Licensing: Significance & Future Prospects
GENA-104(EP0089) Out-Licensing: Significance & Future Prospects INVESTOR RELATIONS 2025 Target Preclinical Development Antibody Phase 1 IND Clinical Development & Discovery & Development & Stages Discovery Approval Commercialization Validation CMC Roles Out-Licensing Feb 2025 Significance 1 Repeated
Slide 11: Ellipses Pharma's unique Drug Development Strategy
Ellipses Pharma’s unique Drug Development Strategy INVESTOR RELATIONS 2025 “Accelerating Development “De-risked Selection of “Proven Operational Timelines; Superior Assets” Excellence” Risk-Minimizing Business Model” Eliminating delays De-risking asset selection Operational excellence • Innovative f
Slide 12: GENA-104(EP0089) Licensing Decision: Rationale & Expected Benefits
GENA-104(EP0089) Licensing Decision: Rationale & Expected Benefits INVESTOR RELATIONS 2025 Timing of Licensing & Clinical Scope Key Considerations & Expected Outcomes Preclinical Phase 1 (Korea) In-House Development • Estimated Cost: Scenario ~10 Million(USD) Licensing out Preclinical Phase 1 (Korea
Slide 13: GENA-104 Future Revenue Potential & Reference Deals
GENA-104(EP0089) Novel Target Immuno-Oncology L/O: Future Revenue Potential & Reference Deals INVESTOR RELATIONS 2025 GENA-104 (Post-Clinical Development) Potential L/O Deal Case Reference iTeos - GSK Innate - AZ/MedImmune Arcus - Gilead MacroGenics - Incyte Biond - Sanofi Co-Development Co-Developm
Slide 14: CNTN4 Target and potential application as novel ICPi and ADC
ICPi CNTN4 Target and potential application as novel ICPi and ADC GENA- INVESTOR RELATIONS 104 2025 ADC Novel Target (CNTN4) Discovery & GENA-104 – Novel ICPi Antibody Development • Anti-CNTN4 (GENA-104) inhibits CNTN4. → T-cells are activated → Tumor cell elimination/death GENA-104 CNTN4 CNTN4 GENA
Slide 15: CNTN4 is Highly Expressed Across Various Cancer Types
CNTN4 is Highly Expressed Across Various Cancer Types; ICPi GENA- but Minimally Expressed in Normal Tissues. INVESTOR RELATIONS 104 2025 ADC CNTN4 Expression Rate by Cancer Type (IHC Analysis) CNTN4 Expression in Normal Tissues CNTN4 is highly expressed in various cancer types. Body systems Specific
Slide 16: Mutually Exclusive Expression Profiles of CNTN4 and PD-L1
ICPi Mutually Exclusive Expression Profiles of CNTN4 and PD-L1 in Tumor Tissues GENA- 104 ADC Heat Map of CNTN4 and PD-L1 Expression Scores (0 ~ +3) through IHC Analysis for Each Cancer Patient Prostate cancer IHC result Gallbladder cancer Stomach cancer Liver cancer Melanoma Prostate cancer Colon c
Slide 17: High CNTN4 Expression in PD-L1 High Non-Responding Patients
ICPi High CNTN4 Expression in PD-L1 High Non-Responding Patients GENA- 104 ADC Analysis of Gastric Cancer Patient Cohort Treated with Anti-PD-1 Overall Response Rate (ORR) of patients Proportions of responders and non-responders within subgrouped by median expression levels of CNTN4–low and –high gr
Slide 18: CNTN4 Expression Affects Survival Rate
ICPi CNTN4 Expression Affects Survival Rate GENA- 104 ADC Overall Survival Overall survival 100 Low Probability of Survival High p=0.011 50 Patients with Low CNTN4 Expression Patients with High CNTN4 Expression 0 0 10 20 30 40 Time (Month) In gastric cancer patients treated with anti–PD-1 therapy, h
Slide 19: Anti-Tumor Efficacy of GENA-104 Across Animal Models
Anti-Tumor Efficacy of GENA-104 Across Animal Models with Varying GENA- ICPi CNTN4 Expression Levels 104 ADC In CNTN4-Expressing CT26 Model In Low CNTN4-Expressing CT26 Model In CNTN4-Negative MC38 Model 1200 4000 2500 hIgG4, 10mg/kg hIgG4, 3mg/kg hIgG4, 3mg/kg GENA-104A16, 1mg/kg GENA-104A16, 1mg/k
Slide 20: Expectations for GENA-104
Expectations for GENA-104 Unmet Needs of PD-(L)1 Potential of GENA-104 Expected Outcome • Success of PD-(L)1 • Key findings from Genome & • If clinical utility is - A new paradigm in cancer Company’s preclinical demonstrated in PD-L1 non- immunotherapy studies: responders, - The most commercially -
Slide 21: GNOCLE Platform
GNOCLE Platform INVESTOR RELATIONS 2025 GNOCLE : A Genomics-Based Platform for Discovering New Therapeutic Targets Nat. Microbio. (2021) Commun. Biol. (2021) Medicine (Baltimore, 2021) Microbiome (2022) Microorganisms (2022) Cancers (Basel, 2021) Human Microbiome Project Biomedicines(2022) Commun. B
Slide 22: Securing Multiple Novel Oncology Targets for ADCs via the GNOCLE Platform
Securing Multiple Novel Oncology Targets for ADCs via the GNOCLE Platform As of January 2025 Developmental Status Modality Pipeline Target Nonclinical Target Hit Lead IND enabling Phase I candidate Debio 0633 Hide 2024.05 License-Out GENA-104 CNTN4 GENA-120 N/D ADC GENA-121 N/D GENA-122 N/D ADC Prog
Slide 23: Components of ADC and Their Respective Roles
Components of ADC and Their Respective Roles INVESTOR RELATIONS 2025 Monoclonal Antibody Linker Payload Role of the • Binds to antigens specifically • Linking the payload with the • Kills cancer cells effectively 3 ADC expressed in tumor tissue → antibody Components Delivers the payload to the tumor
Slide 24: Securing Multiple Novel ADC Targets through the GNOCLE Platform
Securing Multiple Novel ADC Targets through the GNOCLE Platform As of January 2025 Developmental Status Modality Pipeline Target Nonclinical Target Hit Lead IND enabling Phase I candidate Debio 0633 Hide 2024.05 License-Out GENA-104 CNTN4 GENA-120 N/D ADC GENA-121 N/D GENA-122 N/D ADC Programs N/D G
Slide 25: CNTN4 is minimally expressed in normal and immune cells
CNTN4 is minimally expressed in normal and immune cells, suggesting favorable safety ICPi GENA- profile 104 ADC CNTN4 Expression in Normal Tissues CNTN4 Expression in Human Immune Cells (Protein Expression, FACS) CNTN4 Body systems Specific positive tissues (IHC), % Immune cell Activation Population
Slide 26: GENA-104A16 shows strong internalization and anti-tumor efficacy
GENA-104A16 antibody shows strong internalization, a key requirement for ADCs, and ICPi GENA- demonstrated anti-tumor efficacy in preclinical studies INVESTOR RELATIONS 104 2025 ADC Internalization HT1080/CNTN4 Fibrosarcoma CDX Model Internalization of DXd & Exatecan (high DARs) GENA-104A16 FITC Con
Slide 27: Table of Contents
Table of Contents INVESTOR RELATIONS 2025 I. Company Overview II. GENA-104 (EP0089) Out-Licensing III. Microbiome Commercialization (UIQ Cosmetics) IV.Strategy (Vision) The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is
Slide 28: Introduction to the UIQ Brand
Introduction to the UIQ Brand Restoring the microbiome of healthy skin enables anyone to regain skin health Microbiome Epidermis UIQ, [juːik / 유이크 / 유이끄] Dermis A French-sounding word evoking "beneficial bacteria." Skin health-enhancing Subcutaneous fat Brand Vision ‘UIQ' microbiome cosmetics Blood
Slide 29: UIQ's Domestic Strategy & Overseas Strategy
UIQ's Domestic Strategy & Overseas Strategy Domestic Strategy Overseas Strategy Expanding distribution networks in Asia and Eastern Europe, leveraging the current presence in 9 countries Increasing brand awareness Russia • Securing brand awareness through Uzbekistan exclusive model RIIZE and influen
Slide 30: Cosmetics Business Growth
By achieving 8 billion won in sales in 2024, we plan to establish ourselves as a new rising brand. Cosmetics Business Growth Global Japan Inner Beauty Domestic Offline Domestic Online 2021: 2022: Expansion of 2023: Selection of exclusive 2024: Diversification of domestic channels and expansion into
Slide 31: Table of Contents
Table of Contents INVESTOR RELATIONS 2025 I. Company Overview II. GENA-104 (EP0089) Out-Licensing III. Microbiome Commercialization (UIQ Cosmetics) IV.Strategy (Vision) The copyright is owned by Genome & Company. Its purpose is solely for the discussion with our current and potential partners. It is
Slide 32: Genome & Company Commercialization Strategy Progress
Genome & Company Commercialization Strategy Progress INVESTOR RELATIONS 2025 2024 2025~2027 2028~ New Target • Licensing out of new target ADC • Licensing out of new target • Greater value licensing out of new Anti-Cancer antibody worth KRW 580 billion to immunotherapy GENA-104 to Ellipses target AD
Slide 33: Genome & Company Strategy
Genome & Company Strategy INVESTOR RELATIONS 2025 Phase1 : Phase2 : Phase3 : - Achieve 2 L/O deals for new-target - Focus on discovering novel ADC - Achieve major ADC deal with in-house anti-cancer drugs targets Linker-Payload and establish stable - UIQ cosmetics sales expected to reach - Start full
Slide 34: Genome & Company Financial Plan
Genome & Company Financial Plan INVESTOR RELATIONS 2025 New Drug Development and Commercialization Microbiome CDMO Business of Microbiome-Based Therapies • Achieved two out-licensing (L/O) deals for novel targeted anti-cancer drugs R&D • Transferred repetitive-use antibody technology for novel targe
Slide 35: Thank you
Thank you Genome & Company (gnc-ir@genomecom.co.kr)